Regenerative medicine device company RegenLab USA (RGNA.US) sets IPO price at $6–$8 per share, aiming to raise $18 million

According to Golden Ten Data, RegenLab USA, a medical device company focused on regenerative medicine applications such as tissue repair, announced its IPO terms on Tuesday. The Jersey City, New Jersey-headquartered company plans to issue 2.5 million shares at a price range of $6 to $8 per share, raising $18 million. Based on the midpoint of the proposed price range, RegenLab USA’s fully diluted market capitalization will reach $157 million.

RegenLab develops and manufactures disposable devices that allow on-site preparation of autologous platelet-rich plasma (PRP), which can be used alone or combined with hyaluronic acid (HA). Its products are applied in musculoskeletal, wound care, aesthetic medicine, and women’s health fields. The company’s two main products are the PRP preparation kit RegenKit and the PRP-HA composite product Cellular Matrix for knee osteoarthritis. Most products have obtained European CE certification; several RegenKit products, including a wound gel covered by Medicare, have been approved by the US FDA. Cellular Matrix has not yet been approved in the US and is currently undergoing the PMA (premarket approval) process. Founded in Switzerland in 2003, the company has production bases in Switzerland, France, and New Jersey, and sells in approximately 90 countries through a direct sales team and distributors.

RegenLab USA was established in 2003 and achieved $54 million in revenue in the 12 months ending June 30, 2026. The company plans to list on Nasdaq under the stock code “RGNA”. StoneX Financial is serving as the sole underwriter for this offering.